Select therapeutic use:

Anxiety/OCD:

Indications for Clonazepam Orally-Disintegrating Tabs:

Panic disorder.

Adult:

≥18yrs: initially 0.25mg twice daily; after 3 days increase to 1mg/day; then may increase every 3 days by 0.125–0.25mg twice daily; max 4mg/day. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.

Children:

<18yrs: not established.

Contraindications:

Significant liver disease. Acute narrow-angle glaucoma.

Warnings/Precautions:

Increased risk of drug-related mortality from concomitant use with opioids. Suicidal thoughts or behavior (monitor). Depression. May increase or precipitate tonic-clonic seizures. Compromised respiratory function (eg, COPD, sleep apnea). Porphyria. Renal impairment. Avoid abrupt cessation. Monitor blood counts, liver function during long-term therapy. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

See Also:

Pharmacologic Class:

Benzodiazepine.

Interactions:

Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A4 (eg, fluconazole). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, lamotrigine, phenobarbital); monitor.

Adverse Reactions:

CNS effects (eg, somnolence, depression), confusion, amnesia, liver disorders, GI upset, blood dyscrasias, paradoxical reactions (discontinue gradually if occur); hypersalivation.

How Supplied:

Tabs—100; Orally-disintegrating tabs—contact supplier.

Seizure disorders:

Indications for Clonazepam Orally-Disintegrating Tabs:

Lennox-Gastaut syndrome, akinetic and myoclonic seizures. Absence seizures refractory to succinimides.

Adult:

Initially up to 0.5mg 3 times daily. Increase if needed every 3 days by 0.5–1mg daily; max 20mg daily. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.

Children:

≤10yrs or ≤30kg: initially 0.01–0.03mg/kg per day, but not >0.05mg/kg per day in 2–3 divided doses. Increase if needed every 3 days by 0.25–0.5mg daily. Maintenance: 0.1–0.2mg/kg per day in 3 equally divided doses. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.

Contraindications:

Significant liver disease. Acute narrow-angle glaucoma.

Warnings/Precautions:

Increased risk of drug-related mortality from concomitant use with opioids. Suicidal thoughts or behavior (monitor). Depression. May increase or precipitate tonic-clonic seizures. Compromised respiratory function (eg, COPD, sleep apnea). Porphyria. Renal impairment. Avoid abrupt cessation. Monitor blood counts, liver function during long-term therapy. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

See Also:

Pharmacologic Class:

Benzodiazepine.

Interactions:

Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A4 (eg, fluconazole). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, lamotrigine, phenobarbital); monitor.

Adverse Reactions:

CNS effects (eg, somnolence, depression), confusion, amnesia, liver disorders, GI upset, blood dyscrasias, paradoxical reactions (discontinue gradually if occur); hypersalivation.

How Supplied:

Tabs—100; Orally-disintegrating tabs—contact supplier.